UBE2N anticorps (AA 20-138) (FITC)

N° du produit ABIN7174474

Détail du produit anti-UBE2N anticorps (FITC)

Antigène: UBE2N (Ubiquitin-Conjugating Enzyme E2N (UBE2N))

Épitope: AA 20-138

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp UBE2N est conjugé à/à la FITC

Application: Veuillez nous consulter SVP

Réactivité croisée: Humain

Purification: >95%, Protein G purified

Immunogène: Recombinant Human Ubiquitin-conjugating enzyme E2 N protein (20-138AA)

Isotype: IgG

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur UBE2N

Antigène: UBE2N (Ubiquitin-Conjugating Enzyme E2N (UBE2N))

Autre désignation: UBE2N (UBE2N Produits)

Synonymes: anticorps UBC13, anticorps UbcH-ben, anticorps UbcH13, anticorps 1500026J17Rik, anticorps AL022654, anticorps BB101821, anticorps ube2n, anticorps wu:fb11b03, anticorps wu:fc08b06, anticorps zgc:55726, anticorps ubc13, anticorps ubch-ben, anticorps UBE2N, anticorps ube2nl, anticorps zgc:63901, anticorps ubiquitin conjugating enzyme E2 N, anticorps ubiquitin-conjugating enzyme E2N, anticorps ubiquitin conjugating enzyme E2 N S homeolog, anticorps ubiquitin-conjugating enzyme E2Na, anticorps ubiquitin-conjugating enzyme E2Nb, anticorps UBE2N, anticorps Ube2n, anticorps ube2n.S, anticorps ube2na, anticorps LOC100533434, anticorps ube2n, anticorps ube2nb

Sujet:

Background: The UBE2V1-UBE2N and UBE2V2-UBE2N heterodimers catalyze the synthesis of non-canonical \'Lys-63\'-linked polyubiquitin chains. This type of polyubiquitination does not lead to protein degradation by the proteasome. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. Acts together with the E3 ligases, HLTF and SHPRH, in the \'Lys-63\'-linked poly-ubiquitination of PCNA upon genotoxic stress, which is required for DNA repair. Appears to act together with E3 ligase RNF5 in the \'Lys-63\'-linked polyubiquitination of JKAMP thereby regulating JKAMP function by decreasing its association with components of the proteasome and ERAD. Promotes TRIM5 capsid-specific restriction activity and the UBE2V1-UBE2N heterodimer acts in concert with TRIM5 to generate \'Lys-63\'-linked polyubiquitin chains which activate the MAP3K7/TAK1 complex which in turn results in the induction and expression of NF-kappa-B and MAPK-responsive inflammatory genes.

Aliases: Bendless like ubiquitin conjugating enzyme antibody, Bendless-like ubiquitin-conjugating enzyme antibody, BLU antibody, EC 6.3.2.19 antibody, Epididymis secretory protein Li 71 antibody, HEL-S-71 antibody, Human epidermoid carcinoma mRNA for ubiquitin-conjugating enzyme E2 similar to Drosophila bendless gene product complete cds antibody, MGC131857 antibody, MGC8489 antibody, UBC 13 antibody, Ubc13 antibody, UbCH ben antibody, UbcH-ben antibody, UbcH13 antibody, UBCHBEN antibody, Ube 2N antibody, Ube2n antibody, UBE2N_HUMAN antibody, Ubiquitin carrier protein N antibody, Ubiquitin conjugating enzyme E2 N antibody, Ubiquitin conjugating enzyme E2N (homologous to yeast UBC13) antibody, Ubiquitin conjugating enzyme E2N (UBC13 homolog yeast) antibody, Ubiquitin conjugating enzyme E2N antibody, Ubiquitin protein ligase N antibody, Ubiquitin-conjugating enzyme E2 N antibody, Ubiquitin-protein ligase N antibody, Yeast UBC13 homolog antibody

UniProt: P61088

Pathways: TCR Signaling, Fc-epsilon Receptor Signaling Pathway, Activation of Innate immune Response, Toll-Like Receptors Cascades, Positive Regulation of Response to DNA Damage Stimulus, Ubiquitin Proteasome Pathway